TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings (DNA – Research ... and fragrance industry. Its platform provides equipment, software, robotic automation, and tools ...

Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) shares are volatile Thursday. The company announced the acquisition of AgBiome’s platform assets and the expansion of its strategic partnership with ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings ... Strategically, the company continues to focus on expanding its cell engineering platform, adding 25 new programs and securing ...

Ginkgo Bioworks has been busy ... and RNA therapies. The platform is designed to deliver more effective specific and durable genetic drugs, according to the company. Last on the list of ...

Gingko Bioworks (NYSE:DNA ... biology startup Synplogen to advance global DNA manufacturing and gene therapy platform services in Japan. Synplogen was spun out of Kobe University’s Graduate ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it ...

Ginkgo Bioworks Holdings Inc ... The company is excited about opening its platform to customer scientists, leveraging existing infrastructure like rack automation and Lab Data as a Service ...

Ginkgo Bioworks will leverage their advanced screening platform for rapid testing of VSEs directly in clients’ cell lines. BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)--Ginkgo Bioworks, Inc ...

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 The presentation details and webcast link will be available on Ginkgo's investor relations website at https ...